scholarly journals PUM1 and RNase P genes as potential cell‐free DNA markers in breast cancer

2021 ◽  
Vol 35 (4) ◽  
Author(s):  
Alexis Murillo Carrasco ◽  
Oscar Acosta ◽  
Jaime Ponce ◽  
José Cotrina ◽  
Alfredo Aguilar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Markers ◽  
Rnase P ◽  
Cell Free Dna ◽  
Free Dna

Emerging Role of Genomics and Cell-Free DNA in Breast Cancer

2019 ◽  
Vol 20 (8) ◽  
Author(s):  
Lorenzo Gerratana ◽  
Andrew A. Davis ◽  
Ami N. Shah ◽  
Chenyu Lin ◽  
Carla Corvaja ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Identification of Somatic Mutations in Thirty-year-old Serum Cell-free DNA From Patients With Breast Cancer: A Feasibility Study

2020 ◽  
Vol 20 (5) ◽  
pp. 413-421.e1
Author(s):  
Mathilde Ritter ◽  
Viola Paradiso ◽  
Patrik Widmer ◽  
Andrea Garofoli ◽  
Luca Quagliata ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Feasibility Study ◽  
Somatic Mutations ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine

Cancers ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 728
Author(s):  
Maria Panagopoulou ◽  
Manel Esteller ◽  
Ekaterini Chatzaki
Keyword(s):  
Breast Cancer ◽  
Treatment Options ◽  
Treatment Monitoring ◽  
Circulating Biomarkers ◽  
Hidden Information ◽  
Cell Free Dna ◽  
Free Dna ◽  
Current Review ◽  
Circulating Cell Free Dna

Breast cancer (BC) is a leading cause of death between women. Mortality is significantly raised due to drug resistance and metastasis, while personalized treatment options are obstructed by the limitations of conventional biopsy follow-up. Lately, research is focusing on circulating biomarkers as minimally invasive choices for diagnosis, prognosis and treatment monitoring. Circulating cell-free DNA (ccfDNA) is a promising liquid biopsy biomaterial of great potential as it is thought to mirror the tumor’s lifespan; however, its clinical exploitation is burdened mainly by gaps in knowledge of its biology and specific characteristics. The current review aims to gather latest findings about the nature of ccfDNA and its multiple molecular and biological characteristics in breast cancer, covering basic and translational research and giving insights about its validity in a clinical setting.

scholarly journals Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients

Oncotarget ◽  
2017 ◽  
Vol 8 (32) ◽  
pp. 52142-52155 ◽  
Author(s):  
Takashi Takeshita ◽  
Yutaka Yamamoto ◽  
Mutsuko Yamamoto-Ibusuki ◽  
Mai Tomiguchi ◽  
Aiko Sueta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Plasma Cell ◽  
Breast Cancer Patients ◽  
Cell Free Dna ◽  
Pik3ca Mutations ◽  
Free Dna ◽  
Er Positive ◽  
Positive Breast Cancer

scholarly journals Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA

2020 ◽  
Vol 40 (11) ◽  
Author(s):  
Zhigang Zuo ◽  
Jiying Tang ◽  
Xiaojun Cai ◽  
Feng Ke ◽  
Zhenzong Shi
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Pik3ca Mutation ◽  
Early Stage Breast Cancer ◽  
Healthy Controls ◽  
Cell Free Dna ◽  
Clinical Sensitivity ◽  
Free Dna ◽  
Urine Specimens ◽  
Circulating Cell Free Dna

Abstract Monitoring of early-stage breast cancer is critical in promptly addressing disease relapse. Circulating cell-free DNA provides a minimally invasive and sensitive means to probing the disease. In a longitudinal analysis of 250 patients with early breast cancer, we compared the circulating cell-free DNA recovered from both plasma and urine specimens. For comparison, 50 healthy controls were also recruited. Specific mutations associated with the disease were profiled to determine the clinical sensitivity and specificity. Correlations of recovered concentrations of cell-free DNA with outcomes were examined to address early prognostication. PIK3CA mutation profiling in both plasma and urinary cell-free DNA showed an agreement of 97.2% compared with the results obtained for tumor tissues. The analysis of healthy controls revealed that cell-free DNA measurements were stable and consistent over time. Over the short 6-month period of monitoring, our analyses showed declines in recovered cell-free DNA; these findings may aid physicians in stratifying patients at higher risk for relapse. Similar results were observed in both plasma and urine specimens (hazard ratios: 2.16 and 2.48, respectively). Cell-free DNA presents a novel and sensitive method for the monitoring of early-stage breast cancer. In the present study, serial measurements of both plasma and urine specimens were useful in probing the disease.

Sign in / Sign up

Export Citation Format

Share Document